BioTalk with Rich Bendis

In this episode of BioTalk, host Rich Bendis welcomes Sona Shah, CEO and Co-Founder of Neopenda, for an inspiring conversation on innovation, impact, and scaling medical technology in underserved markets. Sona shares how a formative experience teaching in rural Kenya ignited her passion for global health, leading to the creation of neoGuard, a wearable vital signs monitor tailored for low-resource settings. They discuss the engineering challenges of building clinical-grade hardware for hospitals with limited infrastructure, the company's growth from Maryland's Relevant Health accelerator, and the deployment of over 350 devices across East and West Africa. Sona also talks about Neopenda's next wave of products, lessons in balancing cost and quality, and the importance of community, resilience, and mission-driven entrepreneurship. Editing and post-production work for this episode was provided by The Podcast Consultant. Sona Shah is the CEO and Co-founder of Neopenda, a company dedicated to improving healthcare access in emerging markets. Neopenda develops innovative medical technologies—such as the neoGuard system—designed to help healthcare providers deliver high-quality care in low-resource settings. The company's mission is to make life-saving technology available where it's needed most. Sona's path into global health innovation began during a semester teaching primary school in Kenya, where she witnessed firsthand the challenges faced by under-resourced healthcare systems. That experience, paired with her background in biomedical engineering, inspired her to co-found Neopenda in 2015. Since then, the company has focused on delivering scalable, impactful solutions to countries including Kenya, Uganda, and Ghana, with a long-term goal of reaching the next billion people who could benefit from better access to care. She remains committed to advancing tech-driven healthcare solutions that make a meaningful difference in the world's most underserved communities.

In this timely episode of BioTalk, returning guest Alex Philippidis, Senior Business Editor at Genetic Engineering & Biotechnology News, joins host Rich Bendis to explore how sweeping changes in U.S. regulatory policy, workforce dynamics, and economic pressures are affecting the biotech industry in real time. Alex breaks down the potential consequences of FDA workforce cuts, particularly for small and mid-sized biotechs that depend on regulatory guidance, and offers perspective on how HHS and NIH budget proposals could reshape the national innovation infrastructure. The conversation covers everything from the impact of tariffs on manufacturing and supply chains to the slowing pace of M&A activity and venture capital investment trends. Alex also shares his insights on IPO strategy shifts, and whether the current biotech environment is poised for a rebound—or a broader realignment with global competitors. This is a must-listen episode for anyone navigating the uncertain waters of biotech in 2025. Editing and post-production work for this episode was provided by The Podcast Consultant. Alex Philippidis is the Senior Business Editor at Genetic Engineering & Biotechnology News (GEN). Specializing in biopharma business news and industry issues, Alex joined GEN in 2011 after covering research institutes at GenomeWeb and editing the BioRegion News newsletter. With over 20 years of experience in journalism, Alex has reported on various topics for newspapers and has been featured in major media outlets such as the New York Times and the BBC.

What does it take to establish Maryland as a powerhouse for biotech commercialization? In this episode of BioTalk with Rich Bendis, Dr. Deborah Hemingway, Founder and Managing Partner of Ecphora Capital, shares her insights on the current investment landscape in the BioHealth Capital Region. She discusses the strategic advantages that make Maryland uniquely positioned for success, the critical gaps that must be addressed, and how state and local governments can provide essential support through tax credits, grants, and economic incentives. Dr. Hemingway also highlights Ecphora Capital's impact, having deployed $15 million in the last two years, and reveals the firm's strategy for future investments, including SPVs and a dedicated fund. With deep experience in medtech commercialization, strategic partnerships, and early-stage investing, she offers valuable perspectives on where the industry is headed in 2025 and how companies can thrive in an evolving biotech ecosystem. Tune in for a compelling conversation on innovation, investment, and the future of biotech in the BioHealth Capital Region. Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com). Dr. Deborah Hemingway is the Founder and Managing Partner of Ecphora Capital, a medtech venture capital firm in Baltimore, Maryland. Ecphora Capital leverages first-look access at world-class medical research and manufacturing institutions and is the first and only entity to achieve the top level of a state tax credit program that refunds 75% of their investment.  Additionally, Dr. Hemingway has profound involvement in the entrepreneurial landscape, having founded, invested in, and held board positions for 53 startup companies over twenty years. She has meticulously sharpened her acumen in medical device commercialization, strategic growth, and investing. She is on the board of directors for Mi-Helper and Novel Microdevices. Dr. Hemingway holds a Ph.D. in biophysics from the University of Maryland, College Park.

In this episode of BioTalk, host Rich Bendis is joined by Amitabh Varshney, Dean of the College of Computer, Mathematical, and Natural Sciences and a Professor of Computer Science at the University of Maryland, College Park. Together, they explore the groundbreaking advancements in artificial intelligence and health computing driven by the University of Maryland (UMD). Dean Varshney discusses the launch of the Artificial Intelligence Interdisciplinary Institute at Maryland (AIM) earlier this year. He shares insights into the vision behind AIM, the strategic hiring of new faculty, the allocation of seed grants, and the development of academic programs in AI, all solidifying UMD's position as a leader in this rapidly evolving field. The conversation also delves into the University of Maryland Institute for Health Computing (UM-IHC), which recently marked its two-year anniversary. Dean Varshney highlights the institute's achievements, including its partnerships with organizations like the FDA and NIH, patent submissions, and collaborations with AstraZeneca and 20/20 Gene Systems. He explains how UM-IHC's efforts are reshaping the intersection of health and technology. Rich and Dean Varshney discuss UMD's commitment to innovation and its role in tackling national challenges through interdisciplinary education, cutting-edge research, and collaborations with industry partners, government agencies, and research institutions. They also reflect on the university's integral role within the BioHealth Capital Region and its contribution to advancing scientific discovery, economic growth, and regional leadership in biotech and health innovation. Tune in to hear how UMD's focus on AI and health computing is shaping the future of education, research, and collaboration. Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com). Amitabh Varshney is Dean of the College of Computer, Mathematical, and Natural Sciences and a Professor of Computer Science at the University of Maryland, College Park. Varshney is currently exploring applications of virtual and augmented reality in several areas, including education, healthcare, and telemedicine. His research focuses on exploring the applications of high-performance visualization in engineering, science, and medicine. He has worked on a number of research areas including visual saliency, summarization of large visual datasets, and visual computing for big data. He has served in various roles in the IEEE Visualization and Graphics Technical Committee, including as its Chair (2008–12). He received the IEEE Visualization Technical Achievement Award in 2004. He is a Fellow of IEEE and a member of the IEEE Visualization Academy.

In this episode of BioTalk with Rich Bendis, Dr. Kolaleh Eskandanian, Vice President and Chief Innovation Officer at Children's National Hospital, discusses her work driving pediatric healthcare innovation. Dr. Eskandanian introduces the BARDA SPARK Accelerator, a groundbreaking initiative focused on advancing medical countermeasures for children, and explains how it aligns with Children's National's mission to lead in pediatric healthcare innovation. She also highlights the unique challenges in developing pediatric medical countermeasures and the importance of partnerships with organizations like Rainbow Babies, Mass General, and others. Additionally, Dr. Eskandanian shares insights into the hospital's role in fostering innovation through the National Capital Consortium for Pediatric Device Innovation (NCC-PDI) and the Children's National Research and Innovation Campus. Join us for an engaging conversation about the future of pediatric healthcare, the opportunities for innovation, and how the SPARK Accelerator is paving the way for advancements that will improve the lives of children worldwide. Editing and post-production work for this episode was provided by The Podcast Consultant. Kolaleh Eskandanian, Ph.D., M.B.A., P.M.P. is Vice President and Chief Innovation Officer at Children's National Hospital, reporting to hospital's Executive Vice President, Physician-In-Chief and Chief Academic Officer. In this capacity, she oversees the Office of Innovation Ventures, the Sheikh Zayed Institute's R&D operations, and has a leadership role in the development of the Children's National Research and Innovation Campus (opening 2020). She is also the executive director of the FDA-funded National Capital Consortium for Pediatric Device Innovation (NCC-PDI), focused on accelerating the path to market for pediatric devices. Eskandanian works with a large network of small and large businesses, nonprofits and government agencies –addressing the unmet medical needs of children. She is the producer of an annual innovation competition that supports small businesses who demonstrate the ability to address a significant medical need in the pediatric space. Eskandanian's expertise includes the full spectrum of product development activities, having held management positions at Accenture, a global management consulting firm, where she directed major product launches for clients. Eskandanian is the co-PI on the FDA-funded Global Pediatric Clinical Trials Network grant and the CTSI-CN lead of the Orphan Product Accelerator.  Eskandanian's own innovations are in the market space, used by millions. She is the lead inventor of the first-ever adverse event reporting system, initially deployed in a research academic environment. This technology and its derivatives have now been in the market for over 10 years. She has had leadership roles in the development of the first web-based trouble entry management system for a Fortune 100 company in the telecommunications sector. She has been a key contributor in securing over $40 million in government funding for two large research enterprises. Prior to joining Children's National, Kolaleh held positions with Intelsat, Accenture and Georgetown University. Her background is in mechanical engineering with a PhD in operations science and an MBA from American University Kogod School of Business.

In this episode of BioTalk, Bill Tompkins, President and CEO of the Montgomery County Economic Development Corporation (MCEDC), discusses the strategies driving Montgomery County's position as a leading bioscience hub. Bill highlights MCEDC's role in reinforcing the region's standing as the third-largest bioscience cluster in the U.S. and shares insights into the new Institute for Health Computing. He also introduces two new venture funds—the Technology Innovation Fund and the Founders Fund—designed to accelerate innovation and support local entrepreneurs. Bill outlines MCEDC's priorities for the upcoming year, emphasizing economic growth, investment opportunities, and fostering collaborations that make Montgomery County a thriving ecosystem for business and life sciences. Bill Tompkins is the President and Chief Executive Officer of the Montgomery County Economic Development Corporation (MCEDC), based in Rockville MD. He leads a team of twenty-five diverse professionals who work to fulfill the mission of making Montgomery County one of the best, most diverse and equitable places to be in business in the country. Bill was previously Executive Vice President and Chief Operating Officer and has been with MCEDC since January of 2019. Bill has a seasoned background in marketing, business operations, strategic planning, and nonprofit management, with most of his career serving as a senior executive in the media and entertainment industries with Fortune 500 companies. Bill also ran a consulting practice which advised companies on strategic business opportunities and brand transformation strategies. From May 2014 until August 2015, Bill was Vice President, Advertising and Marketing at The Philadelphia Tribune. He made a strategic investment in The Tribune to help ensure the long-term sustainability of Black media in the US. In July 2012, he was named President and CEO of the National Newspaper Publishers Association, a Washington based organization, which represents over two hundred Black owned and operated newspapers across the nation. Bill joined the Eastman Kodak Company in 2000 as Chief Marketing Officer for the Entertainment Imaging Business unit and became Vice President and General Manager of the Motion Picture Film Group while also serving as a corporate vice president. Prior to Kodak, Bill spent nineteen years from 1982 until 2000 at The Washington Post Newspaper in a variety of executive positions. His most recent position there was Vice President of Marketing with most of his career spent in the Advertising and Circulation Departments. Bill has been in active leadership positions on several nonprofit Boards including the Mosaic Theater Company of DC where he is Treasurer and the former Chair of the Board, Rockville Economic Development (REDI), Worksource Montgomery and the Advisory Boards of the Universities at Shady Grove and Montgomery Moving Forward. He was previously Chairman, National Kidney Foundation, National Capital Area, member, Board of Directors, California Chamber of Commerce, the Advertising Council, the Studio Theatre, The Washington Convention and Visitors Association, The Boys and Girls Clubs of Greater Washington, the American Black Film Festival Advisory Board, and The Helen Hayes Awards Committee. He is also a member of the Executive Leadership Council, and a graduate of Leadership Washington. Bill is a member of the Economic Club of Washington, the Executive Leadership Council, and a graduate of Leadership Washington. Bill received his MBA from the Harvard Business School where he was a General Motors Fellow and received his BA in Economics, magna cum laude from Tufts University. Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).

In this episode of BioTalk, host Rich Bendis welcomes Ric Hughen, CEO of Linshom Medical, and Talia Feldman, Software Engineer at Linshom Medical, to discuss their groundbreaking advancements in respiratory monitoring technology. As the main winners of the 2024 Crab Trap Competition at the 10th Annual BioHealth Capital Region Week, Ric and Talia share Linshom's mission to improve patient safety through their innovative and accessible respiratory monitoring devices. Ric explains how Linshom is addressing critical gaps in respiratory monitoring by bringing operating-room-quality data to patient bedsides and homes. Talia shares insights from the engineering side, highlighting the challenges and breakthroughs in developing reliable and user-friendly technology. The conversation explores Linshom's roots in the BioHealth Capital Region and how its partnerships and resources have been instrumental to the company's growth. Talia reflects on her experience presenting at the Crab Trap Competition, and Ric discusses how this recognition aligns with Linshom's broader visibility and growth objectives. Looking ahead, Ric and Talia provide a glimpse into Linshom's future, including upcoming milestones and advancements that promise to further revolutionize respiratory care. Don't miss this episode filled with innovation, collaboration, and a vision for transforming patient safety. Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com). Richard Hughen's thirty years of medical device experience spans three Fortune 500 and three start-up companies with two successful exits to date. He is currently CEO of Linshom Medical, a start-up that is first to deliver operating room quality respiratory data to the patient bedside and home. Ric was an investor and member of the executive team that built start-up CSA Medical, from a technology license (U.S. Navy) through product development, animal trials, clinical trials, five FDA clearances, CE mark, three rounds of funding ($50M), commercial growth and a 2019 sale to Steris. Ric was Managing Director of LearnWare, a life science focused e-learning start-up, which was successfully built and sold to a private equity fund. He is currently a reviewer for the National Science Foundation's SBIR/STTR program, an Entrepreneur in Residence for Johns Hopkins Tech Ventures, an advisory board member of George Mason University's Bioengineering Alliance and a site miner for TEDCO at the University of Maryland Medical Center in Baltimore. Earlier in his career, Ric led various senior management, marketing, training and sales teams for Johnson & Johnson, BD, Abbott and Cordis. Ric holds MBA and BS degrees from The Pennsylvania State University. Talia Feldman is a software engineer at Linshom Medical, an innovative healthcare technology company at the forefront of transforming respiratory monitoring. Talia received a B.S. in Computer Science with a concentration in Artificial Intelligence from the University of Delaware. Upon graduation she worked as a software engineer in the Maritime Division at Leidos. Now combining her technical skills with a passion for innovation, Talia supports Linshom Medical's development of providing continuous predictive respiratory monitoring to improve patient care.

In this episode of BioTalk with Rich Bendis, Dr. Eric Edwards, Co-Founder and CEO of MedPhlow, shares how his innovative company is reshaping emergency medicine through cutting-edge drug delivery systems. Dr. Edwards discusses his journey from co-founding Kaléo, where he helped develop life-saving products like AUVI-Q, to leading MedPhlow, a subsidiary of Phlow Corp. Based in Richmond, VA, MedPhlow is dedicated to addressing critical challenges in essential medicine delivery, with its first product focused on improving outcomes during sudden cardiac arrest. Dr. Edwards explains the groundbreaking technology behind MedPhlow's platform and how it is poised to transform emergency care. He also highlights the impact of investor partnerships, such as those with Virginia Venture Partners, and discusses MedPhlow's next milestones in its mission to make emergency medicine more efficient and accessible. As a part of the BioHealth Capital Region, Dr. Edwards reflects on the advantages of being based in this vibrant hub of innovation and his contributions as a BioHealth Innovation (BHI) board member. Tune in to learn about the future of MedPhlow and the inspiring work being done to advance life-saving solutions in healthcare. Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com). Dr. Edwards was previously co-founder of Kaléo, Inc. a pharmaceutical company in Richmond, VA. During his 16 years at Kaléo, he held several executive management positions including Chief Science Officer where he was responsible for overall scientific strategy and all pharmaceutical development programs; Chief Medical Officer responsible for developing a medical affairs team and capability while operationalizing the Company's clinical program strategy; and Vice President – Innovation, overseeing Kaleo's research and development pipeline and overall new product strategy.   Dr. Edwards is the co-inventor of multiple marketed products, including AUVI-Q, epinephrine auto-injector for the treatment of allergic emergencies (anaphylaxis), is named on over 215 issued and patent-pending applications, and is a published author on numerous scientific publications.   Dr. Edwards also continues to serve his community by volunteering on a local rescue squad, including responding to 911 calls and training paramedics in pre-hospital emergency care. Dr. Edwards. obtained his B.S. in Biology, Ph.D. in the Pharmaceutical Sciences, and Doctor of Medicine degrees at Virginia Commonwealth University/Medical College of Virginia.  

Join us for an insightful episode of BioTalk as Rich Bendis speaks with Eric Mayton, CEO of Cerillo, one of the recent winners at the Crab Trap competition during the 10th Annual BioHealth Capital Region Week. Cerillo, based in Charlottesville, VA, is making waves in microbiome research and biological product development with its innovative tools designed to tackle variability challenges and enhance data collection efficiency.   In this episode, Eric shares Cerillo's mission to combat Eroom's Law—the increasing cost and time in drug development—through affordable and accessible research tools like the Stratus and Alto microplate readers. We also dive into the impact of Cerillo's co-culture duet system, which is transforming cellular interaction studies in fields such as antimicrobial resistance and biofuel development.   Learn how being located in the southern part of the BioHealth Capital Region has supported Cerillo's growth and hear about the company's future plans to further accelerate biological research. Don't miss this conversation about the innovations driving a new era in cellular analytics.   Eric Mayton is the President, CEO, and Chairman of the Board at Cerillo, a Charlottesville, VA based cellular analytics firm focused on increasing the efficiency, reproducibility, and standardization of data collection in scientific research and product development. Eric spent the first decade of his career managing academic and commercial laboratories before earning his MBA from the University of Richmond in 2017.   After stints in private equity and management consulting, Eric returned to the biotech industry in 2020 as CEO of Cerillo, a University of Virginia spin-out. Eric holds a B.S. in Chemistry from the University of Virginia, a M.S. in Biochemistry from Virginia Commonwealth University, and a M.B.A from the University of Richmond.   Editing and post-production work for this episode was provided by The Podcast Consultant (thepodcastconsultant.com).

In this episode of BioTalk, Rich Bendis sits down with Rachel Rath, the Head of JLABS @ Washington, DC, to discuss her journey and insights on building a thriving ecosystem for life sciences innovation. Rachel shares her academic and professional background, from roles at PCORI and BARDA Blue Knight to leading JLABS @ Washington, DC. She offers an in-depth look at JLABS' national and international footprint, and the significant partnerships with organizations like Children's National, Virginia Tech, and BARDA that strengthen the innovation landscape across the mid-Atlantic.   Tune in as Rachel shares the current priorities at JLABS, highlighting the diversity of its tenant portfolio, which spans MedTech, Pharma, and Integrated Healthcare Solutions. She also discusses how JLABS companies benefit from the support and resources available through Johnson & Johnson, including access to valuable connections, mentorship, and funding opportunities via JJDC.   Located in the heart of the BioHealth Capital Region, JLABS @ Washington, DC is well-positioned to drive collaboration and ecosystem growth. Rachel sheds light on the unique advantages of this strategic location and shares her views on addressing the challenges faced by life science startups, from funding access to investment connectivity, and the vital steps needed to elevate the region's biohealth ecosystem.   Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).   Rachel is responsible for setting the strategic direction and overseeing all operational activities for JLABS @ Washington, DC. Her responsibilities include P&L management, external engagement, innovation sourcing, portfolio management, and operational excellence in collaboration with the team responsible for the site and the region. In addition to managing the business of JLABS, Rachel is responsible for the process of evaluating, selecting and accelerating a strong portfolio of innovators connected to JLABS @ Washington, DC, which supports companies across the broader region.   Prior to this role, Rachel served as the inaugural Director of the BARDA Alliance for Johnson & Johnson Innovation. As BARDA Alliance Director, she was responsible for managing BLUE KNIGHT™, a joint initiative between JLABS and the Biomedical Advanced Research and Development Authority (BARDA), which aims to stimulate the innovation and incubation of science and technologies. Rachel led the strategic direction, alliance management, and oversight of all operational activities related to BLUE KNIGHT™, including managing the sourcing and selection of high potential companies for JLABS locations and developing global programming including the annual BLUE KNIGHT™ Symposium.   Before joining JLABS, Rachel was the Chief of Staff for the National Evaluation System for health Technology Coordinating Center (NESTcc)—an initiative of the Medical Device Innovation Consortium (MDIC)—that was established with funding from the U.S. Food and Drug Administration (FDA) and was recognized in September 2019 as one of the first collaborative communities with participation by the FDA. Prior to joining NESTcc, Rachel worked at PCORI, helping to launch the Patient-Centered Clinical Research Network (PCORnet), a national effort to engage patients and leverage electronic health data to improve the speed and efficiency of clinical research in the United States.   Rachel received her MBA from Georgetown University and MPH in global health policy from The George Washington University.

In this episode of BioTalk, Rich Bendis speaks with Dr. Frank Gupton, Co-Founder of Phlow and CEO of the Medicines for All Institute, about his pioneering efforts to improve pharmaceutical manufacturing and global access to essential medications. Dr. Gupton shares how Phlow is addressing vulnerabilities in the U.S. pharmaceutical supply chain by producing critical medicines domestically, and how the Medicines for All Institute is reshaping the way drugs are made by reducing costs and streamlining production. Drawing on his extensive experience in the pharmaceutical industry, Dr. Gupton discusses the ongoing challenges of ensuring that lifesaving medicines reach those in need worldwide. The discussion also touches on the future of pharmaceutical manufacturing, from emerging technologies like continuous processing to green chemistry's role in creating more sustainable production methods. Dr. Gupton provides insight into how partnerships and collaboration are vital to accelerating these innovations. Join the conversation to hear about the impactful work being done to transform drug manufacturing and access on a global scale. Dr. Frank Gupton is a professor at Virginia Commonwealth University and holds joint appointments in the Departments of Chemistry and the Department of Chemical and Life Science Engineering. He is the Floyd D. Gottwald Chair of Pharmaceutical Engineering and also serves as Department Chair of the Chemical and Life Science Engineering Department. His thirty-year industrial career centered on the development and commercialization of chemical processes for pharmaceutical applications. Dr. Gupton's research group is currently focused on the development of continuous processing technology to facilitate the discovery, development and commercialization of drug products. Prior to joining the faculty at Virginia Commonwealth University, Dr. Gupton served as the Executive Director of North American Process Development for Boehringer Ingelheim Pharmaceuticals and led the commercialization of the widely prescribed HIV drug nevirapine. Dr. Gupton received his Bachelors of Science degree in chemistry from the University of Richmond and graduate degrees in organic chemistry from Georgia Tech and Virginia Commonwealth University. Dr. Gupton's research efforts have focused on streamlining pharmaceutical processes, particularly in the area of active ingredients, by employing the principles of process intensification which include the use of innovative chemistry, novel continuous manufacturing platforms, and new and more efficient catalysts for pharmaceutical applications. The research group's efforts are guided and driven based on both financial and economic impact that can be derived from this effort. Dr. Gupton is the recipient of the 2018 American Chemical Society Award for Affordable Green Chemistry, and in the same year, he received the Presidential Award for Green Chemistry. In 2019 he received the Peter J. Dunn Award for Green Chemistry and Engineering Impact in the Pharmaceutical Industry from the ACS Green Chemistry Institute Pharmaceutical Round Table. These awards were associated with Professor Gupton's work on the development of a highly efficient process to produce nevirapine, a first-line treatment in HIV therapy.   Editing and post-production work for this episode was provided by The Podcast Consultant (thepodcastconsultant.com).  

In this episode of BioTalk, Rich Bendis, President and CEO of BioHealth Innovation, Inc., sits down with Peter Ronco, Chief Executive Officer of Emmes, a global full-service Clinical Research Organization (CRO). Peter discusses his transition from leading roles at Janssen R&D and Bristol Myers Squibb to guiding Emmes' strategic direction and operations.   Peter introduces Emmes, its growth as a full-service CRO, and the recent partnership with New Mountain Capital that has accelerated global acquisitions and diversified services. He also discusses the formation of the Emmes Group, which includes Veridix AI, and the latest partnership with Mimansa AI, highlighting the impact of AI in clinical research.   The conversation also covers the strategic importance of Rockville, Maryland, as Emmes' headquarters and why Montgomery County is an ideal location. Peter wraps up by outlining Emmes' future growth plans.   About Peter Ronco: Peter Ronco is the CEO of Emmes, with extensive global experience in pharmaceutical development. He oversees the strategic and operational aspects of Emmes, a leading CRO operating in over 30 countries. Prior to Emmes, Peter held senior roles at Janssen R&D and Bristol Myers Squibb.   Tune in to BioTalk for a focused discussion with Peter Ronco on Emmes' growth, AI in clinical research, and the future of global drug development. Editing and post-production work for this episode was provided by The Podcast Consultant (thepodcastconsultant.com).

In this episode of BioTalk, Rich Bendis, President and CEO of BioHealth Innovation, Inc., welcomes Brad Sibbald, Vice President of Kelly Science and Clinical, and Sarah Porter, Vice President of Government Solutions at Kelly Services. Together, they explore the critical trends and strategies shaping the biotech and government workforce landscapes, with a particular focus on the BioHealth Capital Region (BHCR). Kelly Services, a global leader in workforce solutions, plays a pivotal role in connecting talent with opportunities across various industries, including science, engineering, technology, and telecommunications. Brad and Sarah provide valuable insights into how Kelly Services is adapting to the evolving needs of the biotech sector, from commercial enterprises to government agencies. The discussion covers various topics, including the current talent landscape in the BHCR, strategies for maintaining a robust pipeline, and the challenges of retaining top talent in an increasingly competitive market. Additionally, we learn about Kelly's upcoming virtual job fair in September (https://bit.ly/3yMuiRm), an event for those looking to connect with opportunities in the biotech sector and the 2024 Kelly Global Re:work Report (https://bit.ly/3SSVhBl), offering listeners valuable insights into the future of work and workforce trends globally. About Brad Sibbald: Brad Sibbald is the Vice President of Kelly Science and Clinical, with over 15 years of experience in workforce solutions and consultative services. With a background in biochemistry and a passion for innovation, Brad is committed to driving forward-thinking solutions in the biotech industry. About Sarah Porter: Sarah Porter is the Vice President of Government Solutions at Kelly Services, leading the sales and operations for Kelly Government Solutions. With nearly 20 years of experience in the government industry, including a role at the NIH, Sarah has a deep understanding of the complexities of workforce solutions in the federal sector. Tune in to BioTalk for an insightful discussion with Brad Sibbald and Sarah Porter as they explore workforce trends, talent strategies, and the evolving landscape of biotech and government solutions in the BioHealth Capital Region and beyond. Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).

In this special episode of BioTalk, Rich Bendis, President and CEO of BioHealth Innovation, Inc., hosts a compelling discussion with three groundbreaking guests from South Africa: Johann de Bruyn, CEO of TASK, Ethan Hunter, Chief Operations Officer at Immobazyme, and Dr. Carla Eksteen, Postdoctoral Research Fellow at Stellenbosch University. Together, they share their journey of connecting South Africa's biotech scene with the BioHealth Capital Region, showcasing how innovation transcends borders.   Johann de Bruyn opens the conversation by introducing TASK Applied Science and its collaborative relationship with the U.S. He explains the genesis of Bio Centrifuge Africa, a business plan competition inspired by the BioHealth Capital Region's Crab Trap, designed to bridge the gap between South Africa's emerging biotech sector and the established BHCR.   Ethan Hunter, co-founder of Immobazyme, discusses his company's pioneering work in precision fermentation and the growing impact it has across various industries. He reflects on the significance of winning Bio Centrifuge Africa and the exciting opportunity to compete in the 9th Annual Crab Trap in Maryland this September.   Dr. Carla Eksteen shares her research journey in cancer immunotherapy and the vital role her work plays in advancing healthcare in South Africa. She talks about the opportunities provided by Bio Centrifuge Africa and her upcoming trip to Maryland as part of the competition winners.   This episode offers a fascinating look at how South African innovators are making their mark on the global biotech stage and emphasizes the power of international partnerships in driving the industry forward.   About Johann de Bruyn: Johann de Bruyn is the CEO of TASK Applied Science, committed to integrating Africa into the global clinical research landscape. With a diverse background in management, Johann is passionate about advancing healthcare and elevating Africa's role in global clinical research.   About Ethan Hunter: Ethan Hunter is the Chief Operations Officer and co-founder of Immobazyme, a South African biotechnology company specializing in precision fermentation. With a strong foundation in plant biotechnology and molecular biology, Ethan is leading Immobazyme's innovative efforts in the biotech industry.   About Dr. Carla Eksteen: Dr. Carla Eksteen is a Postdoctoral Research Fellow at Stellenbosch University, focusing on cancer research and immunotherapy. With significant experience in tackling chemotherapy treatment resistance and tumor immunogenicity, Dr. Eksteen is dedicated to advancing precision oncology in South Africa.   Tune in to BioTalk for an enlightening discussion with Johann de Bruyn, Ethan Hunter, and Dr. Carla Eksteen as they share their experiences and vision, linking South African biotech innovation with the BioHealth Capital Region.   Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).  

In this episode of BioTalk, Rich Bendis, President and CEO of BioHealth Innovation, Inc., welcomes guests from ARPA-H: Craig Gravitz, Director of the Project Accelerator Transition Innovation Office (PATIO), and Jenica Patterson, Ph.D., Portfolio Lead at ARPA-H. Together, they provide a comprehensive overview of ARPA-H's mission and innovative programs.   Craig Gravitz and Jenica Patterson share their educational and career backgrounds, setting the stage for a discussion about ARPA-H and its various initiatives. They provide insights into how ARPA-H differentiates itself from other agencies like HHS and NIH, while also highlighting their collaborative efforts.   Listeners will learn about the Project Accelerator Transition Innovation Office (PATIO) and its crucial role within ARPA-H. Jenica Patterson discusses her portfolio, including key areas and projects, and provides details on the new women's sprint for health initiative and its funding tracks.   The conversation highlights examples of ARPA-H investments and milestones achieved, as well as the processes involved in determining future programs and investment priorities. Craig and Jenica also discuss the unique Entrepreneur in Residence (EIR) program and how it supports ARPA-H projects.   About Craig Gravitz: Craig Gravitz is designing and implementing the transition and commercial strategy for the Advanced Research Projects Agency for Health (ARPA-H).  Prior to joining ARPA-H, Mr. Gravitz launched and ran a research and development program at the Defense Logistics Agency. He is a licensed attorney and has previously serviced as a contracting officer.   About Jenica Patterson, Ph.D.: Jenica Patterson, Ph.D is a Portfolio Lead at ARPA-H within the Project Accelerator Transition Innovation Office (PATIO) and leads the Sprint for Women's Health. Formerly Dr. Patterson served as the Director of the Technology Transfer and Transition (T3X) Division in the PATIO office, where she oversaw public-private partnerships for transition and the small business program for ARPA-H. Dr. Patterson received her Ph.D in Neuroscience at the University of Maryland, Baltimore County (UMBC) and served as a Science and Technical Advisor at the Defense Advance Research Project Agency, and a Program Director at NIH prior to joining ARPA-H.   Tune in to BioTalk for an informative discussion with Craig Gravitz and Jenica Patterson as we explore the innovative work of ARPA-H and its impact on health research and development.

In this episode of BioTalk, Rich Bendis, President and CEO of BioHealth Innovation, Inc., speaks with Alex Philippidis, Senior Business Editor at Genetic Engineering & Biotechnology News. Alex joins the podcast to discuss the latest Top 10 U.S. Biopharma Clusters list, where the BioHealth Capital Region secured its #3 ranking for the second consecutive year.   The conversation highlights the factors that contributed to the success of the top biopharma clusters, focusing on early investments in biotech, the generation of high-quality science, building networks with partners, and broadening clusters beyond anchor businesses. Alex elaborates on how these regions have sustained their scientific excellence and the long-lasting impact of pioneering efforts.   We explore the criteria used for ranking U.S. biopharma clusters, including NIH funding, venture capital funding, laboratory space, and the number of jobs. Alex provides insights into the methodologies and data sources, such as the NIH RePORT database, PitchBook, and regional life sciences groups, that underpin these rankings.   About Alex Philippidis: Alex Philippidis is the Senior Business Editor at Genetic Engineering & Biotechnology News (GEN). Specializing in biopharma business news and industry issues, Alex joined GEN in 2011 after covering research institutes at GenomeWeb and editing the BioRegion News newsletter. With over 20 years of experience in journalism, Alex has reported on various topics for newspapers and has been featured in major media outlets such as the New York Times and the BBC.   Tune in to BioTalk for an insightful discussion with Alex Philippidis as we explore the latest trends and developments in U.S. biopharma clusters, and the ongoing success of the BioHealth Capital Region.  

In this episode of BioTalk, Rich Bendis, President and CEO of BioHealth Innovation, Inc., speaks with Matt Gardner, Head of Life Sciences, Americas, at CBRE. With over 30 years of experience in the technology and life sciences sectors, Matt Gardner provides a comprehensive look at the latest trends and developments in the life sciences industry.   Matt shares key findings from CBRE's recently released 'U.S. Life Sciences Talent Trends' report for 2024 (https://www.cbre.com/insights/books/us-life-sciences-talent-trends-2024), offering insights into what the life sciences sector can expect in the coming year. He discusses the national real estate market, highlighting the differences between office space and life science wet lab space, and emerging trends in the sector.   The conversation explores the strategic importance of the BioHealth Capital Region (BHCR), consistently ranked as a top market for life sciences research talent. Matt elaborates on what makes this region crucial for CBRE and the life sciences sector as a whole.   We also hear about how CBRE has contributed to the growth and development of the life sciences ecosystem in the BHCR, with Matt sharing examples of key projects and initiatives that stand out. Looking ahead, he outlines CBRE's plans for further expanding and enhancing its presence and services in the region, highlighting upcoming projects and investments.   Matt addresses the dynamic nature of the life sciences real estate market, discussing some of the biggest challenges in the BHCR and how CBRE is positioning itself to address these challenges while capitalizing on new opportunities.   About Matt Gardner: Matt Gardner leads CBRE's Advisory Life Sciences practice in the U.S., including occupier and investor leasing as well as sales. Before joining CBRE, he served as CEO and co-founder of the California Biomanufacturing Center. He has co-founded and served on the boards of multiple incubators across the U.S., including the Maryland Technology Development Center. Matt has a rich history of supporting life sciences companies and has contributed to numerous publications and NPR's Biotech Nation.   Tune in to BioTalk for an informative discussion with Matt Gardner as we explore the future of life sciences real estate and talent trends, and CBRE's pivotal role in supporting the growth of the BioHealth Capital Region.  

In this episode of BioTalk with Rich Bendis, we have the honor of speaking with the U.S. Ambassador to the Republic of Tunisia, Joey R. Hood. With an impressive diplomacy and international relations background, Ambassador Hood sheds light on the vital collaboration between the U.S. and Tunisia in scientific research, innovation, and technology transfer. Host Rich Bendis is the President and CEO of BioHealth Innovation, Inc., dedicated to accelerating biohealth opportunities and fostering innovation across the BioHealth Capital Region of Maryland, Washington D.C., and Virginia….and the world.   Ambassador Hood discusses the current status of U.S.-Tunisia cooperation in scientific research and technology transfer, emphasizing these areas' critical role in Tunisia's development. He highlights the importance of scientific research, innovation, and technology transfer in Tunisia and explains how the U.S. can support and enhance these efforts.   We explore the Department of State-US funded CURES project in Tunisia, examining its goals, progress, and future objectives. Ambassador Hood elaborates on the significance of U.S. funding for projects like CURES and the broader impact on both nations. BioHealth Innovation, Inc. (BHI) is a contractor to FHI 360, supporting the CURES project to assist Tunisia in building its life science research, technology transfer, and commercialization capabilities.   The conversation also covers other key partnerships and projects that the U.S. supports in Tunisia, aimed at fostering research and technology transfer. Ambassador Hood shares insights into these collaborations and his vision for the future of U.S.-Tunisia relations in science and technology.   "The collaborative efforts between the U.S. and Tunisia in scientific research and technology transfer are crucial for advancing innovation and fostering economic growth. The programs we discuss on BioTalk are a testament to the great work happening in this field. I want to thank Ambassador Hood for joining us and sharing his invaluable insights on these important initiatives," says Rich Bendis.   About Joey R. Hood: Joey Hood was confirmed by the U.S. Senate on December 22, 2022. He has held several leadership positions in the U.S. Department of State's Bureau of Near Eastern Affairs, including Acting Assistant Secretary. His extensive diplomatic career includes assignments in Iraq, Kuwait, Saudi Arabia, Yemen, and Qatar. Prior to the Foreign Service, Mr. Hood was a Fulbright scholar in Burkina Faso and worked at a bank in Vermont. He earned a Master's degree from the Fletcher School at Tufts University and a Bachelor's degree from Dartmouth College.   Tune in to BioTalk for an insightful conversation with Ambassador Joey R. Hood as we explore the dynamics of U.S.-Tunisia cooperation in science and technology, and its potential to drive innovation and progress.

Join us for an episode of BioTalk with Rich Bendis featuring Dr. Bradley Maron, Senior Associate Dean for Precision Medicine and Executive Co-Director of the University of Maryland-Institute for Health Computing at the University of Maryland School of Medicine. With his extensive background in cardiovascular research and precision medicine, Dr. Maron offers a wealth of knowledge and innovative perspectives.   In this episode, Dr. Maron shares his professional journey, discussing his various roles at the University of Maryland and what drew him to the region. He provides a comparative analysis of the ecosystems in Boston/Harvard and Maryland/University of Maryland, highlighting the unique attributes and opportunities within each.   Dr. Maron introduces the Institute for Health Computing (IHC), explaining its creation, mission, and strategic partnerships with the University System of Maryland and Montgomery County. He outlines the significance of data science in improving health and wellness, addressing its increasing role and challenges.   We learn about the IHC's approach to bringing learning and healthcare directly to communities, illustrated by an example of their methodology: analyze, innovate, prevent, treat, and adapt. Dr. Maron discusses how the IHC aims to become an economic driver for the University System of Maryland, the state, the BioHealth Capital Region, and the nation, fostering startups, spinouts, commercialization efforts, and entrepreneurial activities.   Dr. Maron outlines the Institute's ambitious goals for the first five years and the range of services to be provided. He also details the decision to establish the IHC in Montgomery County, describing its new facilities and the county's supportive role.   Tune in to BioTalk for an informative discussion with Dr. Bradley Maron as we explore the future of precision medicine and the impactful work of the Institute for Health Computing.  

Radiological Health (CDRH) at the US Food and Drug Administration (FDA). With a distinguished background as a board-certified ophthalmologist and epidemiologist, Dr. Tarver is at the forefront of transforming the evaluation and inclusion of medical devices in underserved and underrepresented populations. In this episode, Dr. Tarver introduces the FDA and the CDRH Division, explaining the definition of a medical device by FDA standards. She discusses the creation of the Chief Transformation Officer role within the FDA, highlighting its importance and the strategic vision behind it. We explore the critical importance of diversity, equity, and inclusion (DEI) in evaluating medical devices, and how these efforts are essential for ensuring equitable healthcare for all. Dr. Tarver introduces the innovative “Home as a Health Care Hub” initiative by the FDA/CDRH, explaining its potential to revolutionize healthcare delivery. Dr. Tarver also addresses the broader transformation needed in the healthcare system to ensure no one is left behind, emphasizing the role of partnerships in achieving this goal. She delves into the role of Virtual Reality (VR) and Artificial Intelligence (AI) in making the home a central hub for healthcare, discussing this ambitious initiative's current status, challenges, and long-term objectives. Additionally, we touch on Dr. Tarver's impressive background, including her leadership roles within the CDRH and her academic achievements at Spelman College and Johns Hopkins University. Finally, we discuss the value of having the FDA in the BioHealth Capital Region and its impact on advancing healthcare innovation. Tune in to BioTalk for an insightful discussion with Dr. Michelle Tarver as we explore the future of medical devices, healthcare transformation, and the pivotal role of the FDA in shaping a more inclusive and innovative healthcare landscape. Dr. Michelle Tarver is a board-certified ophthalmologist and epidemiologist, serving as the Deputy Center Director for Transformation. In this role, Dr. Tarver facilitates the development, implementation, and direction of CDRH's transformative projects and strategic initiatives. Under her leadership, CDRH is advancing efforts to include underserved and underrepresented populations in the evaluation of medical devices. Her CDRH career has included many leadership roles, including the Deputy Director of the Office of Strategic Partnerships and Technology Innovation and the Program Director of Patient Science and Engagement. Dr. Tarver received a B.S. in Biochemistry from Spelman College in Atlanta, GA and completed the M.D./Ph.D. program at The Johns Hopkins University School of Medicine and Bloomberg School of Public Health. 

Join us for an enlightening episode of BioTalk with Rich Bendis as we welcome Dan Berglund, President and CEO of SSTI. With nearly four decades of experience in tech-based economic development (TBED), Dan has been a pivotal figure in shaping the landscape of innovation and entrepreneurship across the nation.   In this episode, Dan shares the history and evolution of Technology Based Economic Development, discussing key initiatives in states like Ohio and Pennsylvania, and at the federal level. He highlights the importance of partnerships, detailing a compendium of state and federal cooperative technology programs that have driven progress in the field.   We explore the early years of SSTI, looking into its creation, mission, and initial goals, and how it has grown to support a nationwide network dedicated to fostering tech-based economies. Dan discusses the evolution and growth of state TBED programs, and the changing role of the federal government in supporting these initiatives through agencies like STCS, OSTP, Commerce, NIST, and EDA.   Dan also emphasizes the importance of private/public TBED partnerships, sharing insights into how these collaborations have bolstered economic growth and innovation. As he prepares to step down from his role after 28 years,and assume a part time role,  Dan discusses the recruitment of a new CEO and reflects on SSTI's achievements, his legacy, and his vision for the organization's future.   Additionally, Dan talks about Rich Bendis's role as an original founding board member of SSTI, and his significant help in the early development of the organization. He also highlights the presence of several SSTI members in the BioHealth Capital Region.   Finally, Dan outlines SSTI's current initiatives and projections for the future, offering a glimpse into the ongoing efforts to support prosperity through science, technology, innovation, and entrepreneurship.   Experience an engaging discussion with Dan Berglund, a leader who has dedicated his career to advancing tech-based economic development and is now ready to embark on a new chapter.   Tune in to BioTalk to gain valuable insights from one of the most influential figures in the field and learn about the future of tech-based economic development.   Dan Berglund is the President and CEO of SSTI, a nonprofit organization dedicated to improving initiatives that support prosperity through science, technology, innovation and entrepreneurship. SSTI is the most comprehensive resource available for those involved in technology-based economic development. Leading SSTI since its inception in 1996, Mr. Berglund has helped SSTI develop a nationwide network of practitioners and policymakers dedicated to improving the economy through science, technology and innovation. SSTI works with this network to assist states and communities as they build tech-based economies, conduct research on best practices and trends in tech-based economic development, and encourage cooperation among and between state and federal programs. Prior to joining SSTI, Mr. Berglund worked as a consultant and for the Ohio Department of Development in a variety of positions, including Acting Deputy Director of the Division of Technological Innovation.

Chief of the Biomolecular Measurement Division at the Material Measurement Laboratory, NIST. With a distinguished career in analytical chemistry and extensive experience in biochemical sensing and bioprocess measurements, Michael leads critical initiatives to advance biotechnology and healthcare.   In this episode, we delve into the pivotal role of NIST as a non-regulatory agency within the Department of Commerce, highlighting its profound impact on measurement science, gene therapy, gene editing, synthetic biology, and regenerative medicine. Michael shares insights into NIST's collaborations, including local companies like MedImmune/AstraZeneca and Novavax, and the importance of partnerships with academic institutions like the University of Maryland in driving local biotech advancements.   We also explore specific technologies and standards such as gene delivery systems, the NIST Monoclonal Antibody Reference Material (NISTmAb), and the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL). Michael discusses the goals for future research and collaborations and reveals the next big developments we should anticipate in the biotech field.   Don't miss this engaging conversation as we uncover the innovations and initiatives at NIST that are shaping the future of biotechnology and healthcare.  

Join us in this episode of BioTalk with Rich Bendis as we delve into the Baltimore ecosystem with Kory Bailey, Chief Ecosystem Officer (CEO) of UpSurge Baltimore, a trailblazing organization dedicated to fostering equitable economic growth and innovation. Kory Bailey brings over a decade of leadership experience from both early-stage startups and big tech. He has emerged as a thought leader on equitable economic growth and a champion for Baltimore's tech ecosystem. As the CEO of UpSurge Baltimore, Kory is spearheading the vision for Baltimore to become the first Equitech hub globally, pioneering a new model for American innovation. In this discussion, Kory unveils UpSurge Baltimore's mission: to cultivate a thriving tech ecosystem for innovators, founders, and talent by fostering culture and connectivity and mobilizing regional and national assets around Baltimore startups. From exploring what drew him to Baltimore to discussing the evolution and unique aspects of UpSurge, Kory shares insights into the philanthropic landscape in Baltimore and initiatives like the Equitech Accelerator, Techstars, KHU, and CareFirst. He also delves into the primary challenges facing Baltimore and UpSurge's short-term goals focused on accountability, awareness, investment, and early-stage support. Join us as we envision Baltimore's future in the next five years and the pivotal role UpSurge Baltimore plays in shaping it. Tune in now to be part of the conversation driving equitable economic growth and innovation in Baltimore's tech ecosystem.

Discover the Future of Healthcare with John Sackett, Executive Vice President & COO of Adventist Healthcare, on BioTalk with Rich Bendis. In this episode, John Sackett shares his insights into the changing landscape of healthcare delivery. From his early days as an administrative assistant to his current role, John's journey offers invaluable lessons on leadership and innovation in the healthcare industry. Join us as we explore Adventist Healthcare's role in the BioHealth Capital Region (BHCR) and explore the transformative changes in healthcare delivery. Gain valuable insights into the challenges and innovations reshaping healthcare post-COVID and learn how Adventist Healthcare is leading the way in patient-centered care. In a candid and inspiring segment, John opens up about his personal journey of managing cystic fibrosis while excelling in his career. Discover the remarkable advancements in the treatment and life expectancy of CF patients, highlighting the power of innovation and resilience in overcoming adversity. Don't miss this enlightening episode as we navigate the evolving landscape of BioHealth Innovation and the BHCR Region with John Sackett, a visionary leader shaping the future of healthcare.

Join us for an engaging episode of BioTalk as we sit down with Lance Kawaguchi, Chief Executive Officer of the Cure Brain Cancer Foundation. Lance's career trajectory from global finance to non-profit leadership is as inspiring as it is impactful, driven by a personal mission to combat brain cancer following the loss of his mother.   In this episode, we explore Lance's journey from senior investment banker to non-profit leader, propelled by personal loss and a vision for change. We delve into the SouthPoleTrek4Cancer initiative, spearheading a global effort to raise awareness and funds for brain and rare cancer charities, culminating in a historic journey to the South Pole. We recognize Lance's leadership achievements, including ringing the Nasdaq bell twice as a cancer charity CEO, and his success in bringing the GBM AGILE Clinical Trial Platform from the US to Australia, accelerating breakthrough research efforts.   We also discuss Lance's strategic plans for growth and impact in the BioHealth Capital Region, driving forward the Cure Brain Cancer Foundation's mission. Additionally, we introduce the esteemed medical and scientific advisory committee steering the foundation's groundbreaking initiatives.   Join us for an insightful discussion as we uncover Lance Kawaguchi's transformative journey and the innovative strides being made in the fight against brain cancer. Tune in to BioTalk and be inspired!  

Are you prepared to discover a transformative shift in orthopedic innovation? Join us in this episode of BioTalk with Rich Bendis as step into the world of Nanochon with CEO Ben Holmes.   Nanochon is leading the charge in the field of medical technology, reimagining the landscape of joint injury treatment. Their inventive implant not only restores damaged cartilage but also fosters fresh tissue growth. Utilizing cutting-edge 3-D printing technology and groundbreaking material, Nanochon's implant serves as both a resilient orthopedic load-bearing device and a scaffold for tissue regeneration. This advancement is poised to redefine patient recoveries, trim healthcare costs, and establish new benchmarks in cartilage rehabilitation.   In this episode, we learn about Nanochon's beginnings, the uniqueness of their technology, the individuals constituting their team, their funding strategies, and the challenges they've overcome.   Don't miss this episode as we venture into the frontier of advanced medical solutions with Nanochon. Tune in now and be part of the conversation reshaping the future of joint health.  

In this episode of BioTalk with Rich Bendis, we're joined by three guests from Solaxa: CEO & Founder Christian Walker, Chief Operating Officer Luis T. Gutierrez, Jr., and Chief Commercial Officer Jennifer Butler. Solaxa is a pioneering biotech company with a mission to revolutionize the treatment of cerebellar ataxias and acute nerve injuries caused by trauma and chemotherapy.   Discover the compelling story behind Solaxa's choice to establish its roots in Montgomery County and how the BioHealth Capital Region has played a crucial role in its growth. Learn how Solaxa's team was assembled, including the inspiring success stories of Luis and Jennifer, both part of the BioHealth Innovation and Montgomery County Maryland's Executive in Residence program.   Hear how Solaxa is making a difference in the world of neurology with SLX-001, a drug showing immense promise in treating cerebellar ataxias. Dive into their innovative approach, including the development of their treatment for cerebellar ataxias.   Additionally, discover how Solaxa's pioneering efforts in this field provide hope for healing. Join us for an enlightening discussion on the future of neurology, innovative treatments, and the remarkable journey of Solaxa.   CEO & Founder Christian Walker has focused his last twenty years pursuing the commercialization of nerve injury solutions. Christian's fundraising experience spans raising money for start-ups, being a start-up venture capitalist, and securing significant non-dilutive financing through grants. At Christian's prior start-ups, Christian was directly responsible for securing $11M in venture financing.   While at Toucan Capital, he served as Principal of a $140 million venture capital fund focused on early-stage investments in stem cells and regenerative medicine. At Johns Hopkins and Walter Reed, he helped secure $22.5M in non-dilutive grants.   Luis T. Gutierrez, Jr. serves as Chief Operating Officer of Solaxa while also serving as an Executive in Residence with BioHealth Innovation.   In both roles, he leverages his 25+ years of expertise in helping novel medical technologies with scientific and clinical promise transition to becoming successful commercial enterprises.    He previously served in executive roles with Veranex, Theralink Technologies, Aptiv Solutions, and Covance.   Chief Commercial Officer Jennifer Butler has 25 years of broad biotechnology industry experience. Her commercial roles at MedImmune, AstraZeneca, and Innate have equipped her with a deep understanding of commercial execution at large and emerging biopharma. Notably, Jen launched Innate's first commercial product in a rare oncology population. Jennifer also is also serving as an Executive in Residence with BioHealth Innovation.  

Have you ever wondered about the true impact of Artificial Intelligence (AI) in the BioHealth industry? In this episode of BioTalk with Rich Bendis, we have the privilege of hosting Dr. Juergen Klenk, a Principal at Deloitte and a Board Member at BioHealth Innovation. Dr. Klenk brings a wealth of expertise and experience with a unique background combining formal scientific training and entrepreneurial ventures.   Join us as we embark on an insightful discussion about the current state of AI in the BioHealth industry, diving deep into the realities and challenges of this cutting-edge technology. Dr. Klenk shares his interest in AI and the reasons behind its increasing prominence in the field. We explore the historical origins of the AI hype cycle and how we've reached the stage we're in today.   Discover tangible examples that illustrate AI's true value, benefits, and impact in BioHealth. Dr. Klenk sheds light on the underlying key technologies that power AI and the associated challenges and risks.   Looking to the future, we examine the outlook for AI in the coming months, years, and even this decade. Will the AI hype continue, or will we witness substantial breakthroughs and transformations? Dr. Klenk offers valuable insights into what organizations can and should do to ride the AI wave effectively.   Don't miss this engaging conversation with Dr. Juergen Klenk as we navigate the exciting world of AI in the BioHealth industry. Tune in now to gain a deeper understanding of AI's reality and its potential to shape the future of healthcare and research.  

Are you ready to dive into the world of groundbreaking biotechnology and the fight against chronic diseases? In this episode of BioTalk with Rich Bendis, we bring you an enlightening conversation with Dr. Nehal Mehta, Founder and CEO of Mobius Scientific, Inc. Dr. Mehta is not only a distinguished Professor of Medicine but also a visionary entrepreneur on a mission to revolutionize healthcare.   Join us as we explore the journey of Mobius Scientific, an early-stage biotechnology company with a transformative approach. Mobius is developing cutting-edge biologic therapies targeting the root cause of chronic diseases, starting with lipid accumulation. This innovative platform has the potential to change the lives of millions suffering from debilitating conditions.   Discover the remarkable story behind Mobius, from its scientific origins and unique name to Dr. Mehta's decision to venture into the world of entrepreneurship. We discuss the science and technology that sets Mobius apart, revealing its pivotal role in addressing age-related macular degeneration (AMD), a leading cause of blindness globally.   Meet the exceptional team and advisors that drive Mobius forward and learn how the company secured its initial funding and gained visibility through strategic contests. Dr. Mehta shares critical milestones and future goals, providing insights into the promising future of Mobius and its mission to combat chronic diseases.   Throughout the episode, we'll also explore how the BioHealth Capital Region has supported the growth and development of Mobius.   Tune in now and be part of the movement to combat chronic diseases with Dr. Nehal Mehta and Mobius Scientific.  

What is the dynamic synergy between pioneering science and transformative industry developments? Join us in this episode of BioTalk with Rich Bendis for a thought-provoking conversation about the work of Blackbird Laboratories. Our guest, Matt Tremblay, Ph.D., Chief Executive Officer of Blackbird Laboratories, sheds light on their role in fostering innovation within the vibrant BioHealth community of Baltimore and the wider BioHealth Capital Region. Blackbird Laboratories recently launched with a significant $100 million founding grant from The Stephen and Renee Bisciotti Foundation. This significant investment aims to bridge the gap between academic research and industry innovation, catalyzing the development of innovative companies, groundbreaking technologies, and a thriving entrepreneurial ecosystem in Baltimore, Maryland. They provide crucial support, including capital, program management, and strategic scientific and business insights, to drive the growth of the BioHealth industry. Their team of seasoned life sciences professionals operates on a value-driven model, committed to reducing the risk of groundbreaking technology for commercialization, attracting crucial investments, nurturing start-ups, and cultivating meaningful public-private partnerships. Their vision is grounded in promoting a thriving ecosystem in Baltimore that will contribute significantly to the growth of the BioHealth sector in the region. In this engaging episode, we'll delve into a diverse range of topics: Meet Matt and Blackbird: Learn about Matt Tremblay's story and gain insights into Blackbird Laboratories' mission, vision, partners, and the exceptional team and advisory board guiding their endeavors. Investment Insights: Explore Blackbird Labs' unique investment philosophy, encompassing the stage, scale, and industries they target. Delve into their specific focus on critical science domains and gain a glimpse into the innovative projects they've already championed. The Baltimore and Maryland Ecosystem: Discover the pivotal role played by Baltimore and Maryland in fostering the growth of the BioHealth Capital Region. Learn about the trailblazers who inspire Blackbird Labs and their strategic efforts to support and empower the regional BioHealth community. Don't miss this insightful episode as we discuss the promising future of BioHealth with Blackbird Laboratories leading the way. Tune in now and become an integral part of the conversation shaping the BioHealth industry's destiny.

Are you ready to explore the transformative world of MedTech and its profound impact on healthcare? Join us in this episode of BioTalk with Rich Bendis as we dive deep into medical technology with an exceptional guest, Neal Piper, Founder & CEO of Luminoah, winner of the 8th Annual BioHealth Capital Region Crab Trap. Neal Piper is the visionary behind Luminoah, a cutting-edge MedTech company dedicated to enhancing the lives of enteral nutrition patients through innovative hardware and software systems. With a background steeped in healthcare, Neal's journey from Pfizer's Neuroscience Division to his role as President of the Global Health Fellows Alumni Business Network has uniquely positioned him to drive change in the industry. But what inspired Neal to create Luminoah? In 2019, his family received a cancer diagnosis for their 3-year-old son, leading to a new reality and a pressing need for a better nutritional feeding program. Neal recognized the challenges faced by patients and caregivers, from bulky equipment to limited data sharing with physicians. That's when Luminoah was born. In this compelling episode, we explore: The origins and mission of Luminoah, driven by a deeply personal experience. The development of the world's first truly portable, connected tube feeding system that's set to revolutionize enteral nutrition. Neal's passion for leveraging technology to transform healthcare and create positive impacts on communities worldwide. Don't miss this enlightening conversation as we journey into the heart of MedTech innovation with Neal Piper. Tune in now and be part of the conversation that's shaping the future of healthcare for enteral nutrition patients.

What are the latest advancements in cancer research and innovation? Join us in this episode of BioTalk with Rich Bendis as we explore the dynamic world of cancer research and technology development with our distinguished guest, Michael Weingarten, Director of the Small Business Innovation Research (SBIR) Development Center at the National Cancer Institute (NCI). Mr. Weingarten plays a pivotal role in leading a team of Program Directors managing the NCI's SBIR & STTR Programs, overseeing a substantial portfolio of $182 million in grants and contracts annually. These programs are at the forefront of NCI's efforts to drive innovation, fostering the development and commercialization of groundbreaking technologies and products for cancer prevention, diagnosis, and treatment. Explore the intersection of the BioHealth Capital Region and the NCI, understanding how collaboration and partnerships are shaping the future of cancer research and innovation. Finally, we delve into the goals for the future, highlighting the NCI's vision and commitment to advancing cancer prevention, diagnosis, and treatment through technology and innovation.

Are you curious about the world of transformative stem cell research? Do you want to learn more about the Maryland Stem Cell Research Fund (MSCRF)? Listen to the latest episode of BioTalk with Rich Bendis as he welcomes MSCRF Executive Director, Ruchika Nijhara, PhD.   Join us in this enlightening episode as we delve into the groundbreaking field of stem cell research with Dr. Nijhara, a visionary leader with a passion for advancing scientific innovation. Discover MSCRF's pivotal role in reshaping healthcare through stem cell research. Explore funding opportunities, real-world project examples, and success stories that highlight the profound impact of this research on healthcare and scientific advancements.   Don't miss this captivating conversation that's shaping the future of scientific innovation. Tune in now and be part of the journey into the transformative world of stem cell research.  

Are you interested in exploring cutting-edge autoimmune medicines? In this episode of BioTalk with Rich Bendis, we're delving deep into the world of transformative therapies with two remarkable guests, Dr. Chris Chapman and Dr. Adam Kaplin, from MyMD Pharmaceuticals. MyMD Pharmaceuticals is on a mission to make that a reality. Their lead clinical candidate, MYMD-1®, has the potential to reshape the entire field. But how does MYMD-1 work, and what sets it apart from current treatments? Join us as we unravel the science behind this revolutionary therapy and explore the potential indications and patient populations it could benefit. And that's not all. We also spotlight Supera-CBD, a novel synthetic cannabidiol with incredible potency and anti-inflammatory effects. How could this innovation change the landscape of chronic pain and anxiety management? Don't miss this episode of BioTalk with Rich Bendis as we embark on a journey into the future of autoimmune medicine with MyMD Pharmaceuticals. Tune in now and be part of the conversation.

How can patients help shape the future of scientific innovation? What's the vital role of the patient's voice in developing life-changing medicines? In this captivating episode, fresh off her thought-provoking appearance at the 9th Annual BioHealth Capital Region Forum, Dr. Theresa Podrebarac takes us on a journey through the dynamic landscape of autoimmune medicine. Dr. Podrebarac is a renowned physician scientist with a wealth of expertise in the biotech industry. As the Senior Vice President of Clinical Development at Horizon Therapeutics, she's at the forefront of bringing hope to patients with rare, autoimmune, and severe inflammatory diseases. Join us as we explore pivotal questions: What is Horizon Therapeutics' mission, and what are Dr. Podrebarac's primary responsibilities in this quest for life-changing medicines? How has Dr. Podrebarac's background as a rheumatologist influenced her belief in the importance of the patient's perspective in drug development? Discover Horizon's impressive journey in clinical development, with a sharp focus on autoimmune diseases. Dive into Horizon's global presence and the crucial role of its Maryland operations. What are the clinical goals that will shape the future of autoimmune medicine? Don't miss this enlightening conversation that delves into the nexus of science, patient advocacy, and innovation. Tune in now and become part of the future where patients' voices are not just heard but lead the way in shaping a brighter tomorrow. Available on all major podcasting platforms. Theresa Podrebarac, M.D., M.Sc., is a physician scientist with extensive development expertise in the biotech industry. At Horizon Therapeutics, Dr. Podrebarac leads the clinical development function dedicated to bringing medicines for rare, autoimmune and severe inflammatory diseases to patients. Prior to Horizon, Dr. Podrebarac served as chief medical officer at two biotech companies focusing on rare diseases.  She was also vice president, immunology clinical development at AbbVie where she helped develop approved therapies for psoriasis and rheumatoid arthritis. At Biogen, she championed the development of tools and techniques for early clinical proof of concept in diseases including scleroderma and lupus skin disease. Dr. Podrebarac holds a master of science in immunology from the University of Ottawa and a medical doctorate degree from Western University. She completed a postdoctoral fellowship in immunology at Harvard University.

Join us for an insightful episode of BioTalk as host Rich Bendis welcomes back Rachel King, the visionary CEO of the Biotechnology Innovation Organization (BIO), bringing with her a remarkable journey spanning roles as an entrepreneur, board member, and advocate for the biotech industry. In this engaging installment, Rachel offers a glimpse into her evolution from consulting to industry, including her role as co-founder and former CEO of GlycoMimetics, Inc. (GMI). Discover the essence of BIO, its mission, and the global perspective it brings to the biotech landscape. Delve into Rachel's advocacy role and the critical issues facing the industry today, including pricing, congressional relations, and investment challenges. Gain insights into the state of the biotech industry and Rachel's projections for both the near and long term. Listen as we unravel the dynamic journey of Rachel King, a trailblazing leader in biotechnology, and gain a comprehensive perspective on the industry's present and future. Available now on all major podcasting platforms.

Explore the world of scientific mentorship and education with Dr. Judy Staveley, an accomplished Chief Biotechnologist and STEM advocate. In this episode of BioTalk, Dr. Staveley discusses her journey in supporting young scientists and her roles in organizations like the National Association of Academies of Science (NAAS) and the American Junior Academy of Science (AJAS).   Discover the upcoming NAAS/AJAS STEM EDUCATION CONFERENCE/FUNDRAISER on September 16th and its impact on inspiring the next generation of innovators. Learn about AJAS's life science support programs that encourage young talents to pursue careers in STEM.   Dr. Staveley shares insights into STEM education in the BioHealth Capital Region and her personal goals for nurturing young scientists. Join us to uncover the pivotal role of mentorship in shaping the future of STEM. Listen now on major podcasting platforms.

What does it take to pioneer groundbreaking T-cell immunotherapies and vaccines for infectious diseases and cancer? Join us for this episode of BioTalk, where we sit down with Bill Enright, a seasoned biotech executive with a remarkable track record spanning over three decades. Bill brings a wealth of experience in building and financing both privately held and publicly traded companies, making his mark in various roles within the life science/biotech industry. Bill offers a compelling update in this installment since his previous appearance on BioTalk. Learn about the intriguing journey that led Vaccitech, a clinical-stage T cell immunotherapy and vaccine company, to select Montgomery County, MD, within the thriving BioHealth Capital Region, for its new site. Delve into the intricacies of their pioneering platform, which harnesses the power of immunotherapy to elicit robust T cell responses and antibodies against infectious agents and tumors. Get an insider's perspective as Bill provides clinical updates on their groundbreaking work, discussing major milestones in critical areas like HBV, HPV, PCA, and VTB, among others. Explore Vaccitech's path forward as Bill sheds light on their next significant milestones and strategic plans to expand their presence within the United States. Don't miss this exclusive conversation with Bill Enright as he shares insights into the dynamic world of immunotherapy and Vaccitech's mission to transform the disease treatment and prevention landscape.

How does a BioPharma Cluster ascend the ranks to secure a Top 3 position? What are the key factors propelling the BioHealth Capital Region to achieve its ambitious goal of ranking 3rd by 2023? Join us in this episode of BioTalk, where our host Rich Bendis speaks with Alex Philippidis, Senior Business Editor at Genetic Engineering & Biotechnology News. In this installment, Alex unveils the intricacies behind his latest Top 10 U.S. Biopharma Clusters, highlighting the impressive rise of the BioHealth Capital Region to its 3rd position. Learn about the origins of these rankings, the trends that have been identified for 2023, and the dynamic shifts within the BioPharma landscape on a regional scale. Discover the journey of the Maryland/Virginia/Washington, DC, BioHealth Capital Region, which has realized its vision of securing a prominent seat among the top echelons of biopharma clusters. With an astounding portfolio of 52,899 patents, this achievement reflects the prolific presence of esteemed institutions such as Johns Hopkins, NIH, and the National Library of Medicine. Tune in to learn about the region's significant accomplishments, including its impressive 6,201 NIH funding awards amounting to $4.245 billion, and a sprawling 31.69 million square feet of cutting-edge lab space. Join us as we unravel the insights that have propelled the BioHealth Capital Region to the forefront of BioPharma innovation and growth.

How does a region evolve to become a leading driver in the BioHealth Capital Region? What are the secrets behind the successful collaboration between various organizations like MCEDC (Montgomery County Economic Development Corporation), MTC (Maryland Tech Council), and the Maryland Department of Commerce? How does a serial biotech entrepreneur leverage his experience to grow a diverse cross-section of businesses, including life sciences, technology, cybersecurity, defense, and hospitality? In this episode of BioTalk, host Rich Bendis chats with Brad L. Stewart, SVP of Economic Development for Montgomery County Economic Development Corporation (MCEDC). Brad's multifaceted career spans from being a Chief Executive Officer to leading expert teams in strategy and innovation, plus economic development specialists in Montgomery County. Together, they delve into the MCEDC Life Science support programs, the remarkable evolution of the region over the last 20 years, Brad's new role as Chair of MTC, and the shared values and collaboration in the region. They also celebrate Brad's achievements and discuss the current state of the Life science industry, especially in MOCO and BHCR. Join this engaging conversation to uncover the strategies and insights that have shaped Montgomery County's economy and the life sciences field. Learn from Brad's leadership and his ability to thrive on complex strategic opportunities. Tune in to this episode of BioTalk to explore the innovative and collaborative spirit that's driving growth and success in the industry.

Ever wondered how public-private partnerships can make a significant difference in the field of life sciences? Curious about the goals, expected impacts, and timeline of the Alliance for Building Better Medicine (ABBM)? Interested in exploring the transformative potential of the Virginia BioHealth ecosystem and its role in advancing the life sciences industry? In this episode of BioTalk, join host Rich Bendis as he interviews Joy Polefrone, Ph.D., Executive Director of the Alliance for Building Better Medicine (ABBM). Joy brings two decades of diverse business leadership and organizational strategy experience. They discuss career shifts in academia, industry, and non-profits, the creation and mission of ABBM, consortium building for the Build Back Better Challenge, funding and match partners, goals and expected impacts, the Virginia BioHealth ecosystem, and the role of public-private partnerships. Discover how Joy's multifaceted perspective helps resolve complex problems and build leaders, teams, and organizations aligned with their values. Gain valuable insights into the transformative potential of public-private partnerships in the life sciences field. Don't miss this opportunity to hear about future goals and directions for ABBM and learn from Joy's seasoned leadership in the industry. Tune in to this engaging episode of BioTalk.

Join us on a compelling episode of BioTalk as we sit down with three dynamic leaders from groundbreaking MedTech companies based in the thriving BioHealth Capital Region. These companies, JuneBrain, Xcision Medical Systems, and Sonavi Labs, were recently selected for the prestigious MedTech Innovator Accelerator, the world's largest accelerator of medical technology companies. Discover their innovative solutions and the transformative impact they are making in healthcare. In this episode, we delve into the cutting-edge advancements and game-changing technologies developed by our esteemed guests. Dr. Samantha Scott, Founder, and CEO of JuneBrain, shares insights on how their remote diagnostic tools utilizing retinal image data are revolutionizing disease progression evaluation, particularly in underserved communities. Ellington West, Co-Founder and CEO of Sonavi Labs, discusses the power of AI in respiratory disease detection and management and its future implications in transforming diagnostics. Michelle Crawley, President of Xcision Medical Systems, sheds light on the GammaPod system and how it disrupts the traditional breast cancer treatment model by delivering higher doses of radiation. Our conversation also explores the significance of being part of the MedTech Innovator Accelerator, the opportunities it offers, and how it helps these companies connect with leading manufacturers, providers, and investors in the industry. We delve into the rigorous application and selection process that set these companies apart from over 1,150 applicants, highlighting their unique contributions to the field of MedTech. We discuss the invaluable role of the BioHealth Capital Region in nurturing and propelling these companies forward. Discover how the region's ecosystem, resources, and talent have facilitated their growth, allowing them to impact patient care and medical advancements. Join us for this captivating episode as we explore the future of MedTech innovation, the power of AI, and the transformative potential of cutting-edge technologies in the BioHealth Capital Region.

Are you curious to discover how experts navigate the complex landscape of life sciences real estate? Want to stay ahead of the curve in the market today? Ready to learn about the latest talent dynamics in the field? Join Rich Bendis on BioTalk as he discusses the world of life sciences real estate and market trends with CBRE's experts, Dan Grimes, Senior VP at CBRE's Mid-Atlantic Life Sciences practice, and Ian Anderson, Senior Director of Research and Analysis. Together, they discuss the 2023 “US Life Sciences Research Talent Report” and the BioHealth Capital Region's Top 3 ranking. Discover how Dan's expertise in real estate strategies for BioHealth companies and investors shapes success in the industry. Gain valuable insights from Ian's extensive experience in commercial real estate and capital markets as he guides decision-making in the life sciences, office, and healthcare sectors. They discuss major BioHealth projects, delve into talent dynamics, and analyze market trends. This conversation offers valuable perspectives, from the evolution of the “US Life Sciences Research Talent Report” to the changing landscape of the top 25 US metros and emerging hubs. Gain a comprehensive understanding of the intricate world of life sciences, from real estate strategies to talent dynamics and market trends. Don't miss this opportunity to gain exclusive insights from CBRE's experts and decode the complexities of life sciences on BioTalk with Rich Bendis.

In this captivating episode of BioTalk, Rich Bendis sits down with Tom Sadowski, the Executive Director of the Maryland Economic Development Corporation (MEDCO). With over 30 years of experience in economic development, Tom has played a pivotal role in translating vision into action. Together we explore MEDCO's significant contributions to economic development and their strategic partnerships across Maryland. Tom shares his remarkable career accomplishments, including successful projects valued at over $10 billion and the creation of 50,000 jobs. His expertise in fostering research partnerships, technology commercialization, and his role in launching the Maryland Momentum Fund bring invaluable insights to the conversation. We uncover MEDCO's focus on real estate development, financing, infrastructure, and public/private partnerships, all aimed at fueling business retention, development, and employment growth. Join us as we discover how MEDCO's innovative financing, strategic advisory services, and collaborative approach attract new businesses, create employment opportunities, and contribute to Maryland's thriving economy. Through this engaging discussion, we witness the transformation from vision to action and delve into the impact of MEDCO's partnerships with public and private entities. Tune in to BioTalk with Rich Bendis and gain a deeper understanding of MEDCO's pivotal role in economic development. Explore the power of vision, collaboration, and the dedicated efforts of J. Thomas Sadowski, along with the entire MEDCO team, in shaping Maryland's business landscape.

Can you envision a world where precision medicine transforms healthcare as we know it? Tune in to this exciting episode of BioTalk with Rich Bendis, featuring Dr. Amrie Grammer, Co-Founder of Ampel BioSolutions. In this enlightening discussion, Dr. Grammer unveils the secrets behind Ampel's remarkable success in precision medicine, making this episode a must-listen. Learn about the groundbreaking genomic tests developed by Ampel, providing decision support for autoimmune diseases, and delve into the role of artificial intelligence in predicting potential treatments. Explore the immense potential for a revolution in healthcare as Dr. Grammer shares insights on understanding the human genome and Ampel's cutting-edge work in harnessing Big Data and Machine Learning for personalized precision medicine. Don't miss this great episode and gain valuable insights into the future of data-driven health.

Join us for an enlightening episode of BioTalk with Rich Bendis as we explore the pivotal role of patient registries in rare disease research and treatment. Our guest, Harsha Rajasimha, MS, Ph.D., CEO of Jeeva Informatics Solutions and Founder and Executive Chairman of IndoUSrare, shares his extensive experience in clinical genomics data science and precision medicine. In this episode, Dr. Rajasimha introduces Jeeva Informatics Solutions and IndoUSrare, his non-profit organization. He discusses the importance of patient registries in accelerating rare disease research, the current obstacles in the field, and the potential solutions. We discuss the role of governments in rare disease research and treatment and the potential for collaboration with non-profits in clinical trials. Finally, Dr. Rajasimha shares the goals of the upcoming Indo-US Rare Summit at the GMU Campus in Arlington, VA. Tune in for valuable insights from a leader in rare disease research and patient advocacy.

Join us on an informative episode of BioTalk with Rich Bendis as we delve into the fascinating realm of computer systems validation (CSV) and its significant impact on quality assurance in the life sciences industry. Our guest, Mr. Gaurav Walia, Senior Global Director of Business Development at PQE Group and Principal SME of Computer Systems Validation, Computer Software Assurance, and Data Integrity and Sr. Associate Partner, brings extensive expertise in CSV and compliance consulting services. Discover the essential role of CSV in ensuring the integrity, reliability, and compliance of computerized systems used in pharmaceutical and medical device manufacturing. Mr. Walia, a recognized authority in the field, will provide insights into CSV's challenges and best practices, emphasizing the critical importance of regulatory adherence and data integrity.

What if the future of medicine could be personalized, predictive, and empowered by data? In this episode of BioTalk, Rich Bendis discusses this topic with Dr. Leroy Hood and Dr. Nathan Price, the co-authors of the book "The Age of Scientific Wellness: Why the Future of Medicine Is Personalized, Predictive, Data-Rich, and in Your Hands." Together, they discuss the scientific revolution reshaping the healthcare and medicine landscape. Dr. Hood and Dr. Price shed light on how cutting-edge technologies, such as genomics and artificial intelligence, are enabling the shift from reactive medicine to proactive, individualized care. They explore the concept of "scientific wellness," where data-rich insights revolutionize disease prevention and unlock the potential for extended health span. Join us on BioTalk for this thought-provoking exploration of the new frontier of medicine, where health optimization is at the forefront.

How will protein engineering unleash a new era of therapeutic possibilities for BioHealth and the BioHealth Capital Region? Join us on this episode of BioTalk with Rich Bendis as we chat with Dr. Luis Alvarez, Founder & CEO of Theradaptive, who is at the forefront of protein engineering technology. Learn about Theradaptive's ingenious approach to overcoming the challenges of naturally occurring proteins, elevating the efficacy and safety of therapeutics through precision-targeted delivery, and mitigating off-target side effects. From spinal fusion and orthopedics to soft tissue repair and targeted chemotherapeutics, Theradaptive's breakthrough technology is set to transform the lives of millions grappling with debilitating conditions linked to loss of tissue function. Be part of the conversation that's unlocking a world of untapped potential in the convergence of protein engineering and therapeutic discovery

Ready to explore the frontiers of cancer therapeutics? Discover how AUM Biosciences is revolutionizing the development of innovative oncology medicines and transforming the fight against cancer resistance. Join us on this episode of BioTalk with Rich Bendis as we chat with Vishal Doshi, Chairman & CEO of AUM Biosciences, a visionary leader in the biotech industry. Tune in to the conversation that's sparking new hope in the battle against cancer.

Want to be on the cutting edge of disease treatment? Learn how companies like Immunyx Pharma are on the front lines in the battle against unknown diseases with the JLABS/BARDA Blue Knight program. Seth Salpeter, Co-Founder and CEO of Immunyx Pharma guests on BioTalk with Rich Bendis